Satiety İnjections
The decision to lose weight begins with behavioral interventions and lifestyle changes. In addition, success is achieved with regular use of early satiety injections.
Behavioral interventions should be continued in those who start an anti-obesity medication.
The choice of antiobesity drug depends upon medication efficacy and adverse effects. For most patients, the incretin-based medications tirzepatide and semaglutide are preferred because they are the most efficacious for weight loss.
Alternative options include other glucagon-like peptide 1 (GLP-1) receptor agonists (eg, liraglutide), phentermine-topiramate, naltrexone-bupropion, orlistat, and phentermine.
Candidates for drug therapy are people who have not achieved weight loss goals with extensive lifestyle intervention.
The patient must have a body mass index (BMI) of ≥30 kg/m2 or a BMI of 27-29.9 kg/m2 and additionally have a weight-related comorbidity.
The effectiveness of injections or pills used against obesity may vary from patient to patient. Likewise, side effects may vary from patient to patient.
Clinical trials which evaluating the efficacy of antiobesity satiety injections have demonstrated 10 to 21 percent weight loss when added to lifestyle modification.
If weight loss exceeds 5 percent of initial weight over three months with therapeutic doses of medication, treatment is considered effective and treatment is continued.
When the maximum therapeutic effect is achieved, weight loss pauses or stops. This does not mean that the drug has “stopped working”. This means further weight loss will require additional strategies.
Finally, if drug therapy is stopped, weight gain is expected.
Close monitoring of patients is essential to minimize the potential risks and side effects of these treatments.
Antiobesity drugs are also used as combined therapy. It can be used in patients who cannot reach their target weight after obesity surgery or who regain weight after reaching their target weight.
